BTS 67582
Latest Information Update: 23 Jan 2013
At a glance
- Originator Abbott GmbH & Co. KG
- Class Antihyperglycaemics; Guanidines; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 23 Jan 2013 Discontinued - Phase-II for Type-2 diabetes mellitus in France (PO)
- 23 Jan 2013 Discontinued - Phase-II for Type-2 diabetes mellitus in United Kingdom (PO)
- 23 Jan 2013 Discontinued - Phase-II for Type-2 diabetes mellitus in USA (PO)